Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
PLASMA-LYTE 148 AND DEXTROSE 5% IN PLASTIC CONTAINER vs ISOLYTE E W/ DEXTROSE 5% IN PLASTIC CONTAINER
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Plasma-Lyte 148 and Dextrose 5% is an intravenous solution that provides maintenance fluid, electrolytes, and calories. Dextrose provides energy and prevents ketosis. Plasma-Lyte 148 contains electrolytes (sodium, potassium, magnesium, calcium, chloride, acetate, gluconate) to replace losses and maintain acid-base balance.
Isolyte E with Dextrose 5% provides isotonic fluid, electrolytes (sodium, potassium, magnesium, chloride, acetate, gluconate), and calories (dextrose). Dextrose supplies glucose for cellular energy, electrolytes maintain acid-base balance and osmotic pressure, and acetate/gluconate serve as bicarbonate precursors to correct metabolic acidosis.
For use as an intravenous source of water, electrolytes, and calories in patients who require fluid and electrolyte replacement and caloric intake,Off-label: treatment and prevention of hypovolemia, maintenance of fluid and electrolyte balance in perioperative settings
Fluid and electrolyte replacement in patients with normal or mildly depleted intravascular volume,Treatment and prevention of hypokalemia,Metabolic acidosis correction,Caloric supplementation when peripheral parenteral nutrition is indicated
IV infusion at a rate of 10-20 m L/kg/hour, not to exceed 100 m L/hour in adults without cardiac or renal compromise; adjust based on fluid status and serum electrolytes.
Intravenous infusion; dose based on electrolyte deficits and maintenance requirements; typical adult maintenance: 50-100 m L/hour, up to 2-3 L/day.
Not applicable as it is a balanced electrolyte solution with dextrose. Components distribute and are eliminated rapidly; dextrose half-life ~15-30 minutes in normoglycemia.
Not applicable (dextrose and electrolytes are endogenous substances; distribution and elimination are rapid, with a functional half-life of minutes to hours depending on infusion rate and renal function).
Dextrose is metabolized via glycolysis and the citric acid cycle to carbon dioxide and water, producing energy. Acetate and gluconate are metabolized in the liver and tissues to bicarbonate. Electrolytes are not metabolized but are excreted or reutilized.
Dextrose is metabolized via glycolysis and the citric acid cycle. Acetate is metabolized primarily in the liver and muscle to bicarbonate. Gluconate is converted to glucose or metabolized via the pentose phosphate pathway.
Components are excreted renally. Dextrose is metabolized; electrolytes are eliminated via kidneys (sodium, chloride, acetate, gluconate, magnesium, potassium). No biliary or fecal elimination.
Renal: 100% (as free water and electrolytes, not metabolized). Biliary/Fecal: negligible.
Electrolytes and dextrose have negligible protein binding (<1%). No significant binding.
Negligible (<5%) for dextrose and electrolytes; no specific binding proteins.
Vd approximates extracellular fluid volume: ~0.15-0.25 L/kg for electrolyte components; dextrose distributes into total body water (~0.6 L/kg).
Dextrose: ~0.2 L/kg (total body water); Electrolytes: ~0.4 L/kg (extracellular fluid). Clinical meaning: distributes throughout total body water.
Intravenous: 100% (by definition). Not administered via other routes.
Intravenous: 100%.
If GFR < 30 m L/min, reduce infusion rate by 50% and monitor potassium and phosphate levels closely; avoid in severe renal impairment if hyperkalemia or hyperphosphatemia is present.
Monitoring of electrolytes and volume status required; dosage adjustment not standardized; avoid in severe renal impairment (e GFR <30 m L/min/1.73 m²) due to risk of hyperkalemia and fluid overload.
No specific Child-Pugh-based adjustment required; use with caution in severe hepatic impairment due to risk of fluid overload and electrolyte disturbances.
No specific adjustment recommended; monitor electrolytes and acid-base balance; caution in severe hepatic impairment due to altered fluid clearance.
Neonates and children: IV infusion at 5-10 m L/kg/hour, titrated to clinical need; maximum rate 20 m L/kg/hour; monitor electrolytes frequently.
Weight-based: 100-150 m L/kg/day for maintenance; adjust for ongoing losses; use with caution in neonates and children with renal impairment.
Start at lower infusion rate (5-10 m L/kg/hour) due to age-related decline in renal function; reassess fluid status regularly to avoid volume overload.
Consider reduced starting rates due to decreased renal function and increased risk of fluid overload; monitor electrolytes and volume status closely; adjust rate based on comorbidities.
Not approved for use in patients with known hypersensitivity to any component. Not for use as a primary source of nutrition in neonates or low birth weight infants due to risk of aluminum toxicity.
NOT FOR USE IN HYPERLACTATEMIA, SEVERE METABOLIC ALKALOSIS, OR SEVERE HEPATIC FAILURE; CONTAINS ALUMINUM WHICH MAY BE TOXIC WITH PROLONGED USE IN RENAL IMPAIRMENT; ADDITIVES MAY BE INCOMPATIBLE, CONSULT PHARMACIST.
Risk of fluid overload and electrolyte disturbances, especially in patients with renal impairment, heart failure, or severe dehydration,May cause hyperglycemia, particularly in diabetic patients,Monitor serum electrolytes, blood glucose, and fluid balance during infusion,Aluminum toxicity with prolonged use in renal impairment,Do not administer simultaneously with blood products through same IV line
Monitor serum electrolytes, fluid balance, and blood glucose. Use with caution in patients with heart failure, renal impairment, hepatic disease, or hyperglycemia. Hypersensitivity reactions may occur. Avoid rapid or large-volume infusion in patients with impaired glucose tolerance.
Hypersensitivity to any component,Clinically significant hyperglycemia,Severe hyponatremia, hyperkalemia, or hypercalcemia,Patients with anuria or severe oliguria not due to hypovolemia
Hypernatremia, hyperkalemia, hypermagnesemia, hypercalcemia, hyperlactatemia, severe metabolic alkalosis, severe hepatic failure, hyperglycemic states, anuria, or known hypersensitivity to any component.
No direct food interactions. However, dextrose content may affect blood glucose; patients with diabetes should monitor glucose levels closely and adjust insulin/oral hypoglycemic agents as directed. Use with caution in patients on sodium or potassium-modifying diets.
No known food interactions. However, patients with diabetes should be aware of dextrose content which affects blood glucose. Dietary potassium or magnesium restriction may be necessary if electrolyte imbalances occur.
Plasma-Lyte 148 and Dextrose 5% is an intravenous electrolyte and carbohydrate solution. At therapeutic doses, no direct fetal toxicity or teratogenicity is expected as electrolytes and dextrose are physiological substances. However, careful monitoring is required during pregnancy to avoid fluid overload, electrolyte imbalances, or hyperglycemia, which could indirectly affect fetal development. No specific trimester-specific risks are identified.
No evidence of teratogenicity in animal studies or human data. Dextrose and electrolytes are essential nutrients; no structural anomalies attributed. However, hyperglycemia in uncontrolled maternal diabetes may cause fetal malformations. Use cautiously in gestational diabetes.
Plasma-Lyte 148 and Dextrose 5% is compatible with breastfeeding. Electrolytes and dextrose are normal blood components that are transferred into breast milk in small amounts, not expected to cause adverse effects in the infant. M/P ratio is not applicable as it is a mixture of physiological substances.
Dextrose and electrolytes pass into breast milk but are normal milk constituents. No adverse effects expected in term infants. M/P ratio not determined as these are endogenous substances. Consider maternal fluid/electrolyte status.
Pharmacokinetic changes during pregnancy (increased plasma volume, altered renal function) may require adjustments in infusion rate and total volume to maintain electrolyte and glucose homeostasis. Dose should be individualized based on maternal weight, clinical status, and laboratory values; no fixed dose adjustment is required.
No specific dose adjustment needed. Monitor for volume expansion in pregnancy (increased intravascular space). Adjust rate based on maternal glucose, electrolytes, and clinical response. Avoid excess dextrose in gestational diabetes.
PLASMA-LYTE 148 and Dextrose 5% is an isotonic solution containing electrolytes and dextrose. Use within 24 hours of spiking the container. Avoid administering through the same line as blood products due to risk of hemolysis from electrolyte content. Monitor serum glucose, electrolytes, and fluid balance, especially in patients with impaired renal function, diabetes, or heart failure. The solution has a p H of ~5.5; consider compatibility with co-administered drugs.
ISOLYTE E W/ DEXTROSE 5% is an isotonic, balanced electrolyte solution with 5% dextrose for parenteral replacement of fluid and electrolytes. It contains potassium, magnesium, and acetate (bicarbonate precursor). Avoid in patients with hyperkalemia, hypermagnesemia, or metabolic alkalosis. Monitor serum electrolytes, glucose, and renal function. Use with caution in heart failure, renal impairment, and patients at risk for fluid overload. Do not administer if cloudy or precipitate present. Discard any unused portion.
This solution provides fluids and sugar to help maintain hydration and energy.,Tell your healthcare provider if you have diabetes, heart problems, or kidney disease.,You may experience swelling, shortness of breath, or changes in urination; report these immediately.,Your blood sugar and electrolyte levels will be monitored during treatment.,Do not use this solution if it is cloudy, discolored, or contains particles.
This solution provides fluids, sugar, and electrolytes to correct imbalances.,Your healthcare team will monitor your blood sugar and electrolyte levels during treatment.,Report any symptoms like swelling, shortness of breath, or changes in urination.,This medication is given only in a hospital or clinic setting by a healthcare professional.,Tell your doctor if you have any allergies, especially to corn (dextrose source).
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about PLASMA-LYTE 148 AND DEXTROSE 5% IN PLASTIC CONTAINER vs ISOLYTE E W/ DEXTROSE 5% IN PLASTIC CONTAINER, answered by our medical review team.
PLASMA-LYTE 148 AND DEXTROSE 5% IN PLASTIC CONTAINER is a Intravenous Electrolyte Solution that works by Plasma-Lyte 148 and Dextrose 5% is an intravenous solution that provides maintenance fluid, electrolytes, and calories. Dextrose provides energy and prevents ketosis. Plasma-Lyte 148 contains electrolytes (sodium, potassium, magnesium, calcium, chloride, acetate, gluconate) to replace losses and maintain acid-base balance.. ISOLYTE E W/ DEXTROSE 5% IN PLASTIC CONTAINER is a Intravenous Electrolyte Solution with Dextrose that works by Isolyte E with Dextrose 5% provides isotonic fluid, electrolytes (sodium, potassium, magnesium, chloride, acetate, gluconate), and calories (dextrose). Dextrose supplies glucose for cellular energy, electrolytes maintain acid-base balance and osmotic pressure, and acetate/gluconate serve as bicarbonate precursors to correct metabolic acidosis.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between PLASMA-LYTE 148 AND DEXTROSE 5% IN PLASTIC CONTAINER and ISOLYTE E W/ DEXTROSE 5% IN PLASTIC CONTAINER depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of PLASMA-LYTE 148 AND DEXTROSE 5% IN PLASTIC CONTAINER is: IV infusion at a rate of 10-20 m L/kg/hour, not to exceed 100 m L/hour in adults without cardiac or renal compromise; adjust based on fluid status and serum electrolytes.. The standard adult dose of ISOLYTE E W/ DEXTROSE 5% IN PLASTIC CONTAINER is: Intravenous infusion; dose based on electrolyte deficits and maintenance requirements; typical adult maintenance: 50-100 m L/hour, up to 2-3 L/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between PLASMA-LYTE 148 AND DEXTROSE 5% IN PLASTIC CONTAINER and ISOLYTE E W/ DEXTROSE 5% IN PLASTIC CONTAINER in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. PLASMA-LYTE 148 AND DEXTROSE 5% IN PLASTIC CONTAINER is classified as Category C. Plasma-Lyte 148 and Dextrose 5% is an intravenous electrolyte and carbohydrate solution. At therapeutic doses, no direct fetal toxicity or teratogenicity is expected as electrolyte. ISOLYTE E W/ DEXTROSE 5% IN PLASTIC CONTAINER is classified as Category C. No evidence of teratogenicity in animal studies or human data. Dextrose and electrolytes are essential nutrients; no structural anomalies attributed. However, hyperglycemia in unco. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.